Real-Life Individual Comparison of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure and Diabetes Mellitus

Mehmet Birhan Yilmaz,Ahmet Celik,Tugce Colluoglu,Anil Sahin,Dilek Ural,Arzu Kanik,Naim Ata,Mustafa Mahir Ulgu,Şuayip Birinci

DOI: https://doi.org/10.1007/s40256-024-00698-6

2024-11-30

American Journal of Cardiovascular Drugs

Abstract:Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are breakthrough agents for the treatment of type 2 diabetes mellitus (T2DM) and heart failure (HF). However, among patients with HF and T2DM, some uncertainty remains about individual comparisons, including dosing.

pharmacology & pharmacy,cardiac & cardiovascular systems